<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7017049/results/search/test_trace/results.xml">
  <result pre="iron chelation. This may be of particular interest for the" exact="treatment" post="of cytopenias after hematopoietic stem cell transplantation, as HCMV"/>
  <result pre="of ganciclovir, eltrombopag is also a drug-repurposing candidate for the" exact="treatment" post="of therapy-refractory HCMV disease. human cytomegalovirus antiviral therapy eltrombopag"/>
  <result pre="as c-Mpl or MPL) agonist that is used for the" exact="treatment" post="of thrombocytopenia, including hepatitis C virus-associated thrombocytopenia [1,2,3]. Its"/>
  <result pre="thrombocytopenia [1,2,3]. Its use has also been suggested for the" exact="treatment" post="of cytopenias after hematopoietic stem cell transplantations and case"/>
  <result pre="the use of ganciclovir (and its prodrug valganciclovir), the mainstay" exact="treatment" post="for cytomegalovirus disease, is associated with severe hematological side"/>
  <result pre="patient who suffered from human cytomegalovirus (HCMV)-associated thrombocytopenia [17]. Immunosuppressive" exact="treatment" post="for thrombocytopenia (prednisone, intravenous immunoglobulin, dapsone), in combination with"/>
  <result pre="ASCs were incubated with HCMV at the indicated multiplicities of" exact="infection" post="(MOIs). After incubation for 1-h, cells were washed with"/>
  <result pre="[18,23], cells producing HCMV-specific antigens were detected 24 h post" exact="infection" post="by immunoperoxidase staining, using monoclonal antibodies directed against the"/>
  <result pre="IEA, MAB8131, Millipore, Temecula, CA, USA), and 120 h post" exact="infection" post="by immunoperoxidase staining, using monoclonal antibodies directed against UL55-encoded"/>
  <result pre="late viral genes. Immediate early genes are transcribed immediately after" exact="infection" post="and do not depend on synthesis of viral DNA"/>
  <result pre="its anti-HCMV effects. Drug addition 1-h or 24 h post" exact="infection" post="was sufficient to achieve maximum inhibition of HCMV LA"/>
  <result pre="cycle characterized by LA expression. Drug addition 48 h post" exact="infection" post="resulted in reduced effects compared to drug addition 1-h"/>
  <result pre="effects compared to drug addition 1-h or 24 h post" exact="infection" post="(Figure 2B, Table S1). 3.2. Eltrombopag Inhibits HCMV Expression"/>
  <result pre="whom eltrombopag is indicated. Eltrombopag has been suggested for the" exact="treatment" post="of cytopenias after hematopoietic stem cell transplantations and case"/>
  <result pre="may be of particular interest for its use for the" exact="treatment" post="of cytopenias after haematopoietic stem cell transplantation, as HCMV"/>
  <result pre="Function after Allogeneic Hematopoietic Stem Cell TransplantationCase Rep. Oncol.20181119119510.1159/00048722929681820 5.TangC.ChenF.KongD.MaQ.DaiH.YinJ.LiZ.ChenJ.ZhuX.MaoX.WuD.TangX.Successful" exact="treatment" post="of secondary poor graft function post allogeneic hematopoietic stem"/>
  <result pre="Sci.201920266610.3390/ijms20112666 11.LjungmanP.de la CamaraR.RobinC.CrocchioloR.EinseleH.HillJ.A.HubacekP.NavarroD.CordonnierC.WardK.N.et al.Guidelines for the management of cytomegalovirus" exact="infection" post="in patients with haematological malignancies and after stem cell"/>
  <result pre="an update of its use in the prevention of cytomegalovirus" exact="infection" post="and disease in transplant recipientsDrugs2001611153118310.2165/00003495-200161080-0001611465876 15.BuscaA.de FabritiisP.GhisettiV.AlliceT.MirabileM.GentileG.LocatelliF.FaldaM.Oral valganciclovir as"/>
  <result pre="transplant recipientsDrugs2001611153118310.2165/00003495-200161080-0001611465876 15.BuscaA.de FabritiisP.GhisettiV.AlliceT.MirabileM.GentileG.LocatelliF.FaldaM.Oral valganciclovir as preemptive therapy for cytomegalovirus" exact="infection" post="post allogeneic stem cell transplantationTranspl. Infect. Dis.2007910210710.1111/j.1399-3062.2006.00183.x17461994 16.MatsumotoK.ShigemiA.IkawaK.KanazawaN.FujisakiY.MorikawaN.TakedaY.Risk factors"/>
  <result pre="differentiation of human adipose-derived stem cellsMethods Mol. Biol.201170228929821082410 20.CinatlJ.Jr.KotchetkovR.ScholzM.CinatlJ.VogelJ.U.DrieverP.H.DoerrH.W.Human cytomegalovirus" exact="infection" post="decreases expression of thrombospondin-1 independent of the tumor suppressor"/>
  <result pre="to protein-based drug carrier systemsBiochem. Biophys. Res. Commun.20043231236124010.1016/j.bbrc.2004.08.22315451429 39.ZwezdarykK.J.FerrisM.B.StrongA.L.MorrisC.A.BunnellB.A.DhurandharN.V.GimbleJ.M.SullivanD.E.Human cytomegalovirus" exact="infection" post="of human adipose-derived stromal/stem cells restricts differentiation along the"/>
  <result pre="cytomegalovirus strains recovered from two immunocompromised patientsAntimicrob. Agents Chemother.1998424444469527804 45.ChouS.ErcolaniR.J.SahooM.K.LefterovaM.I.StrasfeldL.M.PinskyB.A.Improved" exact="detection" post="of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencingAntimicrob."/>
  <result pre="(A,B), HFFs were infected with HCMV strain Hi91 (multiplicity of" exact="infection" post="(MOI) 0.02). HCMV LA expression was detected 120 h"/>
  <result pre="on HCMV LA expression after 24 h of pre-treatment, after" exact="treatment" post="during the 1-h adsorption period, after drug addition post"/>
  <result pre="treatment during the 1-h adsorption period, after drug addition post" exact="infection" post="following the 1-h virus adsorption period, after drug addition"/>
  <result pre="infection. * p &amp;lt; 0.05 Figure 3 Eltrombopag inhibits HCMV" exact="infection" post="by iron depletion. (A) Representative doseâ€“response curve indicating the"/>
 </snippets>
</snippetsTree>
